PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis.

Front Immunol · 2023 · PMC10027008 · PMID 36949944

Europe PMC DOI

hedged sentences

0.0600

closest p · 1.2× alpha

0.0800

boldest claim

The sentences

close to significanceP = 0.06so close (0.05 < p ≤ 0.1)

Difference between these two subgroups was close to significance (Chi2 = 3.41, df = 1 (P = 0.06), I2 = 70.7%).

also in 459 other papers

tended towards significancep=0.08so close (0.05 < p ≤ 0.1)

Although both subgroups showed significant 2-year OS advantage, the subgroups difference tended towards significance (p=0.08) ( Supplementary Figure 5C ).

also in 32 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.